tarloxotinib

Small moleculeexperimental

Clinical trial activity

5 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2012 (NCT01631279)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cn1cnc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1
Mol. weight
601.87 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • pr610
  • pr610
  • tarloxotinib
  • tarloxotinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05313009Phase 1/Phase 2 (Phase 2)Mar 7, 2022Medical University of South Carolina, Rain Therapeutics Inc.
NCT03805841Phase 2Mar 13, 2019Georgetown University, Rain Therapeutics Inc.
NCT02449681Phase 2Aug 1, 2015Georgetown University, Peter MacCallum Cancer Centre, Threshold Pharmaceuticals
NCT02454842Phase 2Jun 1, 2015Georgetown University, Threshold Pharmaceuticals
NCT01631279Phase 1/Phase 2 (Phase 2)Aug 1, 2012Proacta, Incorporated
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Georgetown UniversityAcademic/Hospital3012015
Rain Therapeutics Inc.For profit2112019
Threshold PharmaceuticalsFor profit2212015
Medical University of South CarolinaAcademic/Hospital1112022
Peter MacCallum Cancer CentreAcademic/Hospital1012015
Proacta, IncorporatedFor profit1112012
6 organizations
Page 1 / 1